In addition, the result revealed that VDAC1 exhibited significantly higher expression levels in many types of malignant tumors such as bladder cancer (BLCA), cholangiocarcinoma (CHOL), chromophobe renal cell carcinoma (KICH), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and stomach adenocarcinomas (STAD). This evidence concerns the gene VDAC1 and lung adenocarcinoma.